| Literature DB >> 21247440 |
Abstract
BACKGROUND: Meta-analysis is a popular methodology in several fields of medical research, including genetic association studies. However, the methods used for meta-analysis of association studies that report haplotypes have not been studied in detail. In this work, methods for performing meta-analysis of haplotype association studies are summarized, compared and presented in a unified framework along with an empirical evaluation of the literature.Entities:
Mesh:
Year: 2011 PMID: 21247440 PMCID: PMC3087509 DOI: 10.1186/1471-2156-12-8
Source DB: PubMed Journal: BMC Genet ISSN: 1471-2156 Impact factor: 2.797
Figure 1A graphical representation of the increasing number of published haplotype-association studies. A search was performed in Pubmed using the terms "haplotype" and "association" from 1997 to 2009. Even though the reference list may include review articles, methodological papers or even irrelevant works, the trend is obvious, especially after 2003 when the HapMap project was presented. The search was conducted during December 2009 and thus the count for 2009 may be an underestimate.
Cross-tabulation of haplotypes by disease status
| Cases ( | Controls ( | |
|---|---|---|
| 1 | 89 | 183 |
| 2 | 14 | 26 |
| 3 | 24 | 22 |
| 4 | 3 | 3 |
The haplotype data obtained in a case-control study on 182 caucasian women concerning the association of p53 haplotypes with breast cancer [108]. The data are presented in the form described by Wallenstein and coworkers [38].
List of the 43 meta-analyses that were used in the empirical evaluation
| ID | Reference | Gene/Locus | Disease/Outcome | SNPs in haplotype | Number of studies | Sample Size | Method of analysis | Data availability | Collaborative analysis | Significant results |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | [ | DRD3 | Schizophrenia | 4 | 5 | 7551 | 1 vs. others | No | No | No |
| 2 | [ | ITGAV | Rheumatoid Arthritis | 3 | 3 | 6851 | N/A | Yes | Yes | Yes |
| 3 | [ | IL1A/IL1B/IL1RN | Osteoarthritis | 7 | 4 | 2908 | 1 vs. others | No | Yes | Yes |
| 4 | [ | FRZB | Osteoarthritis | 2 | 10 | 12380 | 1 vs. others | No | Yes | No |
| 5 | [ | CX3CR1 | CAD | 2 | 6 | 2912 | 1 vs. others | Yes | No | Yes |
| 6 | [ | ALOX5AP | Stroke | 4 | 5 | 5765 | 1 vs. others | No | No | No |
| 7 | [ | ALOX5AP | Stroke | 4 | 3 | 3004 | 1 vs. others | No | No | No |
| 8 | [ | GNAS | Malaria | 3 | 7 | 8154 | 1 vs. others | No | Yes | Yes |
| 9 | [ | GNAS | Malaria | 7 | 6 | 7632 | 1 vs. others | No | Yes | Yes |
| 10 | [ | PDLIM5 | Bipolar Disorder | 2 | 3 | 1208 | 1 vs. others | No | No | No |
| 11 | [ | PDE4D | Stroke | 2 | 4 | 4961 | 1 vs. others | No | No | Yes |
| 12 | [ | TGFB1 | Renal Transplantation | 2 | 4 | 438 | pooled | No | No | Yes |
| 13 | [ | IL10 | Renal Transplantation | 3 | 4 | 348 | pooled | No | No | No |
| 14 | [ | 9p21.3 | CAD | 4 | 5 | 7838 | 1 vs. others | No | Yes | Yes |
| 15 | [ | HLA | SLE | 2 | 3 | 527 | 1 vs. others | No | No | Yes |
| 16 | [ | CTLA4 | Graves Disease | 2 | 10 | 2564 | 1 vs. others | Yes | Yes | Yes |
| 17 | [ | CTLA4 | Hashimoto Thyroiditis | 2 | 5 | 1210 | 1 vs. others | Yes | Yes | Yes |
| 18 | [ | ENPP1 | T2DM | 3 | 3 | 8676 | 1 vs. others | No | No | No |
| 19 | [ | MTHFR | ALL | 2 | 4 | 894 | Log-linear model | No | No | Yes |
| 20 | [ | CAPN10 | T2DM | 3 | 11 | 5862 | 1 vs. others | Yes | Yes | Yes |
| 21 | [ | ADAM33 | Asthma | 5 | 3 | 1899 | pooled | Yes | No | No |
| 22 | [ | NRG1 | Schizophrenia | 6 | 11 | 8722 | 1 vs. others | No | No | Yes |
| 23 | [ | RGS4 | Schizophrenia | 4 | 8 | 7243 | 1 vs. others | No | Yes | No |
| 24 | [ | ADRB2 | Asthma | 2 | 3 | 2060 | N/A | No | No | Yes |
| 25 | [ | ESR1 | Fractures | 3 | 8 | 14622 | 1 vs. others | No | Yes | Yes |
| 26 | [ | VDR | Osteoporosis | 3 | 4 | 2335 | Log-linear model | Yes | No | Yes |
| 27 | [ | ACE | Alzheimer's Disease | 3 | 4 | 1619 | pooled | Yes | Yes | Yes |
| 28 | [ | IGF-I | IGF-I levels | 3 | 3 | 1929 | 1 vs. others | No | Yes | Yes |
| 29 | [ | TF | Stroke | 2 | 2 | 818 | N/A | No | Yes | No |
| 30 | [ | FcgammaR | Celliac Disease | 2 | 2 | 1057 | N/A | Yes | Yes | No |
| 31 | [ | VDR | Fractures | 3 | 9 | 23309 | Logistic regression | No | Yes | No |
| 32 | [ | G72/G30 | Schizophrenia | 2 | 2 | 1541 | N/A | Yes | Yes | Yes |
| 33 | [ | VEGF | ALS | 3 | 4 | 1912 | Logistic regression | Yes | Yes | Yes |
| 34 | [ | BANK1 | Rheumatoid Arthritis | 3 | 4 | 4445 | 1 vs. others | No | Yes | Yes |
| 35 | [ | CYP19A1 | Endometrial Cancer | 2 | 10 | 13283 | Logistic regression | No | Yes | Yes |
| 36 | [ | CRP | T2DM | 3 | 3 | 11876 | N/A | No | No | Yes |
| 37 | [ | 8q24 | Colorectal Adenoma | 4 | 3 | 5385 | Logistic regression | No | Yes | Yes |
| 38 | [ | CYP1A1 | Lung Cancer | 2 | 13 | 2151 | Pooled | No | Yes | Yes |
| 39 | [ | TNFA | Prostate Cancer | 5 | 2 | 4881 | Pooled | Yes | Yes | No |
| 40 | [ | PTGS2 | Prostate Cancer | 4 | 2 | 4881 | Pooled | Yes | Yes | No |
| 41 | [ | AR | Endometrial Cancer | 5 | 2 | 1424 | Pooled | No | Yes | No |
| 42 | [ | MGMT | Head and Neck Cancer | 2 | 3 | 1347 | Pooled | No | Yes | No |
| 43 | [ | SNCA | Parkinson Disease | 2 | 11 | 5344 | 1 vs. other | No | Yes | Yes |
We list the reference, the gene name, the disease, the number of SNPs included in the haplotypes, the number of studies, the total sample size, the method of analysis (N/A: not available), the availability of data, whether the data was collected in a collaborative setting and whether the study reported significant results.
The results obtained using the methods described in this work on the 13 studies that reported complete data that suffice for the analysis to be replicated
| ID/[reference] | Gene/Locus | Disease/Outcome | SNPs in haplotype | Number of studies | Significant results | Fixed effects | Random effects | |||
|---|---|---|---|---|---|---|---|---|---|---|
| β = 0 (summary data) | β = 0 (IPD) | γ = 0 (IPD) | β = 0 (summary data) | β = 0 (IPD) | ||||||
| 2/[ | ITGAV | Rheumatoid Arthritis | 3 | 3 | Yes$$ | 0.2506 | 0.2489 | 0.1564 | 0.3288 | 0.3851 |
| 5/[ | CX3CR1 | CAD | 2 | 6 | Yes$ | 0.0834* | 0.0677* | 0.6263 | 0.0883* | 0.1031* |
| 16/[ | CTLA4 | Graves Disease | 2 | 10 | Yes | <0.0001 | <0.0001 | 0.0371 | <0.0001 | <0.0001 |
| 17/[ | CTLA4 | Hashimoto Thyroiditis | 2 | 5 | Yes | 0.0011 | 0.0010 | <0.0001 | 0.0044 | 0.0072 |
| 20/[ | CAPN10 | T2DM | 3 | 11 | Yes$$ | 0.1152 | 0.1036 | 0.6145 | 0.2243 | 0.1655 |
| 21/[ | ADAM33 | Asthma | 5 | 3 | No | 0.6209 | 0.5508 | 0.4697 | 0.6134 | 0.5503 |
| 26/[ | VDR | Osteoporosis | 3 | 4 | Yes$$ | 0.1458 | 0.3051 | <0.0001 | 0.1480 | 0.5781 |
| 27/[ | ACE | Alzheimer's Disease | 3 | 4 | Yes | 0.0193 | 0.0218 | 0.8906 | 0.0193 | 0.0223 |
| 30/[ | FcgammaR | Celliac Disease | 2 | 2 | No | 0.7331 | 0.7335 | 0.9502 | 0.7331 | 0.7336 |
| 32/[ | G72/G30 | Schizophrenia | 2 | 2 | Yes$$ | 0.7790 | 0.7757 | 0.0001 | 0.5750 | 0.6719 |
| 33/[ | VEGF | ALS | 3 | 4 | Yes$ | 0.0437* | 0.0414 | 0.0691 | 0.0716 | 0.0455* |
| 39/[ | TNFA | Prostate Cancer | 5 | 2 | No | 0.2531 | 0.2515 | 0.6185 | 0.2867 | 0.2511 |
| 40/[ | PTGS2 | Prostate Cancer | 4 | 2 | No | 0.3560 | 0.3550 | 0.2087 | 0.6573 | 0.4829 |
For either fixed or random effects methods, we list the p-values for the tests for the overall association (β = 0) using the summary data based methods and the IPD methods. The results for the IPD methods were obtained from the logistic regression method even though the multinomial logistic regression and the Poisson regression method yield nearly identical results. For the fixed effects IPD methods we also list the p-value of overall test for the heterogeneity (γ = 0).
(*): The significance of the multivariate Wald test (β = 0) contradicts univariate one (β= 0).
($): The initially claimed statistically significant results are contradicted by either the multivariate or univariate Wald tests (random effects).
($$): The initially claimed statistically significant results are contradicted by both the multivariate and univariate Wald tests (random effects).